Key statistics dashboard for Alkermes plc (ALKS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Stock Data
| Price | $46.07 |
| Market Cap | $7.7B |
| Enterprise Value | $8.79B |
| Beta | 0.39 |
| Exchange | NASDAQ |
| Country | IE |
Valuation Multiples
| P/E Ratio | 114.32 |
| Price / Book | 4.24 |
| P/S | 4.63 |
| EV/EBITDA | 40.31 |
| EV/Sales | 5.27 |
| EV/FCF | 39.66 |
| P/FCF | 34.87 |
| Earnings Yield | 0.86% |
| FCF Yield | 2.87% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 84.56% |
| EBIT Margin | 9.38% |
| EBITDA Margin | 13.07% |
| Operating Margin | 7.03% |
| Net Margin | 3.97% |
| Return on Equity | 3.72% |
| Return on Assets | 1.51% |
| Return on Invested Capital | 2.12% |
| Return on Capital Employed | 3.14% |
Financial Health
| Current Ratio | 2.30 |
| Quick Ratio | 1.85 |
| Cash Ratio | 0.77 |
| Debt / Equity | 0.87 |
| Debt / Assets | 35.80% |
| Net Debt / EBITDA | 4.87 |
| Interest Coverage | 1.98 |
Per-Share Data
| Revenue per share | 10.01 |
| Book Value per share | 10.85 |
| Cash per share | 3.94 |
| FCF per share | 1.33 |
| Tangible Book Value per share | -3.28 |
| Dividend per share | 0.00 |
Related companies: ACAD · ACLX · AKRO · ARWR · CRSP · KYMR · PCVX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks